U.S. markets closed
  • S&P Futures

    4,478.50
    +1.00 (+0.02%)
     
  • Dow Futures

    35,133.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    15,294.50
    +4.00 (+0.03%)
     
  • Russell 2000 Futures

    2,264.50
    -0.20 (-0.01%)
     
  • Crude Oil

    82.38
    -0.06 (-0.07%)
     
  • Gold

    1,765.40
    -0.30 (-0.02%)
     
  • Silver

    23.25
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1624
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • Vix

    16.31
    +0.01 (+0.06%)
     
  • GBP/USD

    1.3745
    +0.0018 (+0.13%)
     
  • USD/JPY

    114.3240
    +0.0120 (+0.01%)
     
  • BTC-USD

    62,219.56
    +715.02 (+1.16%)
     
  • CMC Crypto 200

    1,449.48
    -2.16 (-0.15%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Nikkei 225

    29,166.66
    +141.20 (+0.49%)
     

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

MONMOUTH JUNCTION, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Company’s common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab, is approved, Outlook Therapeutics expects to commercialize it as the first and only approved ophthalmic formulation of bevacizumab for use in treating approved retinal diseases in the United States, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Outlook Therapeutics:
Lawrence A. Kenyon
LawrenceKenyon@outlooktherapeutics.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

Media Inquiries:
Emmie Twombly
Media Relations Specialist
LaVoie Health Science
M: 857.389.6042
etwombly@lavoiehealthscience.com